CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions

CAR T-cell therapy has emerged as a potentially transformative immunotherapy for certain B-cell malignancies including relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Unhindered and appropriate access for eligible patients is essential to enable optimal outcomes and depends on effective i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jommi, Claudio, Bramanti, Stefania, Pani, Marcello, Ghirardini, Alessandro, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275825/
https://www.ncbi.nlm.nih.gov/pubmed/35837293
http://dx.doi.org/10.3389/fphar.2022.915342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275825/
https://www.ncbi.nlm.nih.gov/pubmed/35837293
http://dx.doi.org/10.3389/fphar.2022.915342

Ejemplares similares